Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Informatics, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.
Nucleic Acids Res. 2021 Jan 8;49(D1):D1179-D1185. doi: 10.1093/nar/gkaa962.
The US Food and Drug Administration (FDA) and the National Center for Advancing Translational Sciences (NCATS) have collaborated to publish rigorous scientific descriptions of substances relevant to regulated products. The FDA has adopted the global ISO 11238 data standard for the identification of substances in medicinal products and has populated a database to organize the agency's regulatory submissions and marketed products data. NCATS has worked with FDA to develop the Global Substance Registration System (GSRS) and produce a non-proprietary version of the database for public benefit. In 2019, more than half of all new drugs in clinical development were proteins, nucleic acid therapeutics, polymer products, structurally diverse natural products or cellular therapies. While multiple databases of small molecule chemical structures are available, this resource is unique in its application of regulatory standards for the identification of medicinal substances and its robust support for other substances in addition to small molecules. This public, manually curated dataset provides unique ingredient identifiers (UNIIs) and detailed descriptions for over 100 000 substances that are particularly relevant to medicine and translational research. The dataset can be accessed and queried at https://gsrs.ncats.nih.gov/app/substances.
美国食品和药物管理局(FDA)和国家转化医学推进中心(NCATS)合作发布了与受监管产品相关物质的严格科学描述。FDA 采用了全球 ISO 11238 药品中物质识别数据标准,并建立了一个数据库,以组织机构的监管提交和上市产品数据。NCATS 与 FDA 合作开发了全球物质注册系统(GSRS),并为公众利益生产了该数据库的非专有版本。2019 年,在临床开发的所有新药中,有一半以上是蛋白质、核酸疗法、聚合物产品、结构多样的天然产品或细胞疗法。虽然有多个小分子化学结构数据库,但该资源在应用药物物质识别的监管标准以及对小分子以外的其他物质的强大支持方面是独特的。该公共、人工策数据集提供了超过 100000 种物质的独特成分标识符(UNII)和详细描述,这些物质与医学和转化研究特别相关。该数据集可在 https://gsrs.ncats.nih.gov/app/substances 上访问和查询。